The FDA approved AbbVie's Mavyret chronic hepatitis C virus treatment.
Here's what you should know:
1. Mavyret is a once-daily, ribavirin-free treatment for adult chronic hepatitis C virus sufferers. It targets the virus across all major genotypes.
2. AbbVie conducted nine registrational studies, examining more than 2,300 patients across all major HCV genotypes. Clinical trials touted high cure rates across all patient populations.
3. AbbVie claims up to 95 percent of HCV patients would be eligible for treatment with Mavyret.
4. AbbVie executive vice president of research and development and chief scientific officer Michael Severino, MD, said in a release, "With Mavyret, physicians and patients now have a treatment option that is highly effective and has the potential to cure the majority of HCV patients in as short as eight weeks, regardless of genotype."